Bristol-Myers Squibb's Zerit
Executive Summary
FDA Antiviral Drugs Advisory Committee will review stavudine (d4T) for treatment of AIDS during May 20 meeting. Bristol filed the NDAs (20-412 and 20-413) for Zerit in January. The meeting is scheduled to begin at 7:30 a.m. at FDA's Parklawn Building, Conference Rooms D & E